Advancing RNA

ARW ON RNA

money loss, spending, poor financial management-GettyImages-2224880481

Here, in part 2 of this three-part series, I share a few details that came to light about the COGS behind Baby KJ’s therapy production. Obviously, we know why it’s important to keep these figures in mind as we move forward; but I particularly liked Strauss’ reminder that it’s our job to “think systematically about how we’re going to create a safety net of sustainable, accessible product that can be widely distributed at an affordable cost.”

OUR EXPERT NETWORK

From Cell State Reprogramming To The Clinic: Turning The Regulatory Genome Into RNA Medicines (Pt. 2)
Ounzain discusses how regulatory genome biology is being translated into drug discovery, from identifying lncRNA targets to building clinically relevant therapeutics and more.
Why Delivery Is Defining The Next Era Of Neuromuscular Therapeutics
Emerging therapies are being designed to safely deliver oligonucleotides to disease-relevant tissues. Delivery is no longer a technical hurdle to overcome but a strategic lever.
Drugging The tRNA Control System
Drug discovery has usually treated transfer RNA as cellular infrastructure: indispensable, highly conserved, and therefore dangerous to perturb. That description is accurate but incomplete.
Analytical Platforms: The Foundation Of The Next Generation Of RNA Therapeutics
RNA therapeutics are entering a new era where analytical platforms drive scalability, regulatory confidence, manufacturing flexibility, and the development of increasingly complex products.
A New Purification Strategy For The Removal Of dsRNA Impurities From IVT mRNA Products
NIST research introduces a gentle SEC method that separates dsRNA impurities from IVT mRNA by tweaking buffer pH, achieving 81.8% target recovery without transcript damage.

WEBINARS

Targeted LNPs: From Ligand Conjugation To Process Optimization

Automating cell therapy manufacturing without redesigning established workflow

Enhancing Gene Editing Outcomes And Safety for Clinical Translation

Unlocking The Next Wave Of Cancer Vaccines

Imagine The Future: An Enhanced Oligonucleotide Synthesis Process

Your AKTA Oligosynt™ System : It's More Than A Machine

Take The Wheel And Drive Your Oligo Synthesis Where You Want

Five Practical Considerations To Move From Concept To Clinic

MEET ARW

I’ve spent the past 10 years building relationships across the biologics and advanced therapies industry. In addition to hosting conversations and writing thought leadership articles, my goal as the editorial and community director for Advancing RNA is to find creative ways for the RNA (and broader ATMP) space to discuss, debate, and ultimately define a mature RNA therapeutics industry.

Start the conversation by following me on LinkedIn!

RNA HOT TAKES

VIRTUAL EVENTS

More Virtual Events

NEWSLETTER ARCHIVE

More Newsletters